Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07081646 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
A Phase 1 study of Amyloidosis and Refractory AL Amyloidosis, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
- 18
- Study locations
NCT07081646 is a Phase 1 study of Amyloidosis and Refractory AL Amyloidosis that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 91 participants, below the 1,126-participant average among 28 other Amyloidosis trials with a reported enrollment target (92% lower). The trial reports 18 study locations across 13 states.
The verdict
NCT07081646, a Phase 1 study of Amyloidosis and Refractory AL Amyloidosis, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
- 18
- Study locations
Study Summary
Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.
Conditions Studied
Interventions
- DRUG AZD0120
Study Locations (18)
New York
- Research Site - New York
- Research Site - New York
- Research Site - New York
Alberta
- Research Site - Calgary
- Research Site - Calgary
Ontario
- Research Site - Toronto
- Research Site - Toronto
Other
- Research Site - London
- Research Site - London
Arizona
- Research Site - Phoenix
California
- Research Site - San Francisco
Florida
- Research Site - Tampa
Massachusetts
- Research Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2031-02-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07081646
The ClinicalTrials.gov registry entry for NCT07081646 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,126-participant average among 28 other Amyloidosis trials with a reported enrollment target (92% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which AZD0120 is the first listed.
NCT07081646 reports 18 study locations spanning 13 distinct geographic areas - top geographies include New York, Alberta, Ontario.
Frequently Asked Questions
What is clinical trial NCT07081646 about?
NCT07081646 is a clinical study titled "A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.". Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.
What is the current status of trial NCT07081646?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2025-08-18. Estimated completion is 2031-02-14.
What conditions does trial NCT07081646 study?
This clinical trial studies the following conditions: Amyloidosis, Refractory AL Amyloidosis, Relapsed AL Amyloidosis, Light Chain Amyloidosis.
What interventions are being tested in trial NCT07081646?
The interventions under investigation include: AZD0120 (DRUG).
Who is sponsoring clinical trial NCT07081646?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07081646 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
-
Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
RECRUITING · Phase 1
-
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
ACTIVE NOT RECRUITING · Phase 1
-
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
COMPLETED · Phase 1
-
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
RECRUITING · Phase 2
-
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.